

AstraZeneca Development Pipeline

2 February 2006

Line Extensions

Compound	Mechanism	Area under investigation	Phase	Estimated Filing	
				MAA	NDA
CV					
<i>Atacand</i>	angiotensin II antagonist	diabetic retinopathy	III	> 2008	>2008
<i>Crestor</i>	statin	atherosclerosis	III	1H 2007	1H 2007
<i>Crestor</i>	statin	outcomes CHF	III	>2008	>2008
<i>Crestor</i>	statin	outcomes renal	III	2008	2008
<i>Seloken/Toprol-XL</i>	beta-blocker	HCTZ combination	III	Launched	Filed
<i>Exanta</i>	thrombin inhibitor	prevention of stroke in AF	III	Filed**	Filed*
GI					
<i>Nexium</i>	proton pump inhibitor	NSAID GI side effects – symptom resolution	III	Promotable***	Filed
<i>Nexium</i>	proton pump inhibitor	NSAID GI side effects – ulcer healing	III	Launched	Filed
<i>Nexium</i>	proton pump inhibitor	peptic ulcer bleeding	III	>2008	>2008
<i>Nexium Sachet formulation</i>	proton pump inhibitor	GERD	III	Q4 2006	Filed
<i>Nexium</i>	proton pump inhibitor	extra-oesophageal reflux disease	II	>2008	>2008
Neuroscience					
<i>Seroquel SR</i>	D ₂ /5HT ₂ antagonist	schizophrenia	III	3Q 2006	3Q 2006
<i>Seroquel</i>	D ₂ /5HT ₂ antagonist	bipolar maintenance	III	2H 2007	1H 2007
<i>Seroquel</i>	D ₂ /5HT ₂ antagonist	bipolar depression	III	1H 2007	Filed
<i>Seroquel SR</i>	D ₂ /5HT ₂ antagonist	generalised anxiety disorder	III	2008	2H 2007
<i>Seroquel SR</i>	D ₂ /5HT ₂ antagonist	major depressive disorder	III	2008	2008
Onc/infection					
<i>Merrem</i>	carbapenem antibiotic	skin and soft tissue infections	III		Launched
<i>Faslodex</i>	oestrogen receptor antagonist	2 nd line after aromatase inhibitor failure	III	2008	2008
<i>Faslodex</i>	oestrogen receptor antagonist	1 st line advanced breast cancer	III	>2008	>2008
<i>Faslodex</i>	oestrogen receptor antagonist	adjuvant	III	>2008	>2008
<i>Iressa</i>	EGFR-TK inhibitor	head & neck cancer	III	2H 2007	1H 2007
<i>Iressa</i>	EGFR-TK inhibitor	breast cancer	II	>2008	>2008

*AstraZeneca continues discussions with the FDA but the current assessment is that it is unlikely a way forward for *Exanta* registration in the US will be identified.

** Switch to EU centralised procedure

*** Authorities stated these symptoms were already captured within the GERD label. Text stating "No clinical interaction with naproxen or rofecoxib" was approved.

Compound	Mechanism	Area under investigation	Phase	Estimated Filing	
				MAA	NDA
Respiratory					
<i>Symbicort Turbuhaler</i>	inhaled steroid/fast onset, long-acting β_2 agonist	Symbicort Maintenance and Reliever Therapy for asthma (SMART)	III	Filed	
<i>Symbicort</i> pMDI	inhaled steroid/fast onset, long-acting β_2 agonist	asthma	III	Filed*	Filed
<i>Symbicort</i> pMDI	inhaled steroid/fast onset, long-acting β_2 agonist	COPD	III	Filed*	2008

* To be supplemented in 2008 with data supporting two additional strengths.

NCE's

Phase III

Compound	Mechanism	Area under investigation	Phase	Estimated Filing	
				MAA	NDA
CV					
<i>Galida</i>	PPAR agonist	diabetes /metabolic syndrome	III	2H 2007*	2H2007*
AGI-1067 (Atherogenics)	Anti-atherogenic	atherosclerosis	III	1H 2007	1H 2007
AZD6140	ADP receptor antagonist	arterial thrombosis	III	>2008	>2008
Neuroscience					
NXY-059 (Cerovive)	free radical trapping agent	stroke	III	1H 2007	1H 2007
Oncology/Inf					
<i>Zactima</i> (ZD6474)	VEGF/EGF TKI inhibitor with RET kinase activity	NSCLC	III	>2008	>2008
AZD2171	VEGF signalling inhibitor (VEGFR-TKI)	NSCLC and CRC	II/III	>2008	>2008

* Subject to the results of Phase III studies and regulatory discussions

NCE's

Phases I and II

Compound	Mechanism	Area under investigation	Phase	Estimated Filing	
				MAA	NDA
CV					
AZD7009	antiarrhythmic IV	atrial fibrillation – conversion	II	2008	2008
AZD9684	CPU inhibitor	thrombosis	II	>2008	>2008
AZD0837	thrombin inhibitor	thrombosis	II	>2008	>2008
AZD2479 (Avanir)	Reverse Cholesterol Transport enhancer	dyslipidaemia	I	>2008	>2008
AZD6610		dyslipidaemia/ diabetes	I	>2008	>2008
AZD8677		dyslipidaemia/ diabetes	I	>2008	>2008
GI					
AZD9056	Ion channel blocker	inflammatory bowel disease	II	>2008	>2008
AZD3355	inhibitor of transient lower oesophageal sphincter relaxations (TLESR)	GERD	I	>2008	>2008
AZD9343	inhibitor of transient lower oesophageal sphincter relaxations (TLESR)	GERD	I	>2008	>2008
AZD9272		GERD	I	>2008	>2008
Neuroscience					
AZD3480 (TC-1734,Targacept)	Neuronal nicotinic receptor agonist	cognitive disorders	II	>2008	>2008
AZD9272		neuropathic pain	I	>2008	>2008
Onc/Infection					
Zactima (ZD6474)	VEGF/EGF TKI inhibitor with RET kinase activity	medullary thyroid cancer	II	>2008	>2008
CytoFab (Protherics)	anti-TNF-alpha polyclonal antibody	severe sepsis	II	>2008	>2008
ZD4054	endothelin A receptor antagonist	prostate cancer	II	>2008	>2008
Patrin (KuDOS)	AGT inhibitor	solid tumours	II	>2008	>2008
AZD0530	SRC kinase inhibitor	solid tumours and haematological malignancies	I	>2008	>2008
AZD6244 (ARRY-142886)	MEK inhibitor	solid tumours	I	>2008	>2008
AZD1152	Aurora kinase inhibitor	solid tumours and haematological malignancies	I	>2008	>2008
AZD4769		solid tumours	I	>2008	>2008
KU59436 (KuDOS)	PARP inhibitor	breast cancer	I	>2008	>2008
AQ4N (KuDOS)	Hypoxia activated cytotoxic	solid tumours	I	>2008	>2008

Phases I and II (continued)

Compound	Mechanism	Area under investigation	Phase	Estimated Filing	
				MAA	NDA
Respiratory					
AZD9056	ion channel blocker	rheumatoid arthritis	II	>2008	>2008
AZD9056	ion channel blocker	COPD	II	>2008	>2008
AZD8955	collagenase inhibitor	osteoarthritis	II	>2008	>2008
AZD3778	chemokine receptor antagonist	rhinitis	II	>2008	>2008
AZD8309	chemokine receptor antagonist	rheumatoid arthritis	I	>2008	>2008
AZD8309	chemokine receptor antagonist	COPD	I	>2008	>2008
AZD3342	protease inhibitor	COPD	I	>2008	>2008
AZD1981		asthma	I	>2008	>2008

NCE's

Pre Clinical

Compound	Mechanism	Area of investigation	Phase	Estimated Filing	
				MAA	NDA
CV					
AZD8450		dyslipidaemia	PC	>2008	>2008
AZD6370		diabetes	PC	>2008	>2008
AZD8593		haemostasis	PC	>2008	>2008
AZD1175		diabetes/obesity	PC	>2008	>2008
AZD2207		diabetes/obesity	PC	>2008	>2008
AZD1305		arrhythmias	PC	>2008	>2008
AZD1092		diabetes	PC	>2008	>2008
AZD4121		dyslipidaemia	PC	>2008	>2008
GI					
AZD8081		functional GI disease	PC	>2008	>2008
AZD6538		GERD	PC	>2008	>2008
Neuroscience					
AZD3102		Alzheimer's disease	PC	>2008	>2008
AZD1080		Alzheimer's disease	PC	>2008	>2008
AZD2327		anxiety	PC	>2008	>2008
AZD5904		multiple sclerosis	PC	>2008	>2008
AZD6538		neuropathic pain	PC	>2008	>2008
AZD8797		multiple sclerosis	PC	>2008	>2008
AZD3783		anxiety and depression	PC	>2008	>2008
AZD1940		nociceptive and neuropathic pain.	PC	>2008	>2008
AZD9335		neuropathic pain	PC	>2008	>2008
AZD3241		Parkinson's disease	PC	>2008	>2008

Pre Clinical (continued)

Compound	Mechanism	Area of investigation	Phase	Estimated Filing	
				MAA	NDA
Onc/Infection					
AZD9935	VEGF signalling inhibitor (VEGFR-TKI)	solid tumours	PC	>2008	>2008
AZD0424	SRC kinase inhibitor	solid tumours	PC	>2008	>2008
AZD8931		solid tumours	PC	>2008	>2008
AZD4877		solid tumours	PC	>2008	>2008
AZD7762		solid tumours	PC	>2008	>2008
AZD5180 (Abgenix)		solid tumours	PC	>2008	>2008
AZD1845		solid tumours	PC	>2008	>2008
AZD8330		solid tumours	PC	>2008	>2008
AZD3646		solid tumours and haematological malignancies	PC	>2008	>2008
Respiratory					
AZD6067	protease inhibitor	COPD	PC	>2008	>2008
AZD6703		rheumatoid arthritis	PC	>2008	>2008
AZD6357		Osteoarthritis	PC	>2008	>2008
AZD7928		COPD	PC	>2008	>2008
AZD2914		COPD	PC	>2008	>2008
AZD2392		asthma/rhinitis	PC	>2008	>2008
AZD1744		asthma/rhinitis	PC	>2008	>2008
AZD5672		rheumatoid arthritis	PC	>2008	>2008
AZD3825		asthma	PC	>2008	>2008
AZD1236		COPD	PC	>2008	>2008
AZD4818		COPD	PC	>2008	>2008
AZD5069		COPD	PC	>2008	>2008
AZD9668		COPD	PC	>2008	>2008
AZD9215		asthma	PC	>2008	>2008
AZD1678		asthma	PC	>2008	>2008
AZD6605		osteoarthritis	PC	>2008	>2008

AstraZeneca Development Pipeline Discontinued Projects vs HY 28 July 05

CV

NCE/Line Extension	Compound	Area under investigation
NCE	AZD7009 Antiarrhythmic oral	atrial fibrillation – maintenance
NCE	AZD7806	dyslipidaemia
NCE	AZD4619	dyslipidaemia
NCE	AZD8294	dyslipidaemia

Neuroscience

NCE/Line Extension	Compound	Area under investigation
NCE	AZD7371	overactive bladder
NCE	AZD4282	neuropathic pain

Oncology and Infection

NCE/Line Extension	Compound	Area under investigation
NCE	AZD3409	solid tumours
NCE	AZD5438	solid tumours
NCE	ZD6126	solid tumours
NCE	AZD4440	solid tumours

Respiratory and Inflammation

NCE/Line Extension	Compound	Area under investigation
NCE	AZD3778	Indication asthma

Comments

As disclosure of compound information is balanced by the business need to maintain confidentiality, information in relation to some compounds listed here has not been disclosed at this time.

Compounds in development are displayed by phase.

Abbreviations:

PC – Pre-clinical: Candidate Drug accepted for development but not yet administered to man.

MAA - Marketing Authorisation Application (Europe)

NDA – New Drug Application (USA)